<DOC>
	<DOCNO>NCT01951170</DOCNO>
	<brief_summary>This open-label , single-arm study evaluate efficacy safety tocilizumab patient active moderate severe rheumatoid arthritis . Participants receive subcutaneous dose tocilizumab 162 mg weekly . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>An Open-Label Study RoActemra/Actemra ( Tocilizumab ) Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient least 18 year age Patients diagnosis active moderate severe rheumatoid arthritis ( RA ) Oral corticosteroid nonsteroidal antiinflammatory permit stable dose regimen &gt; /= 4 week prior baseline Permitted nonbiologic diseasemodifying antirheumatic drug ( DMARDs ) use alone combination allow stable dose least 4 week prior baseline Receiving treatment outpatient basis , include tocilizumab Females childbearing potential male female partner childbearing potential may participate study use reliable mean contraception least 5 month follow last dose tocilizumab Previous current treatment methotrexate inadequate response methotrexate , intolerance methotrexate treatment methotrexate consider inappropriate Evidence one erosion hand foot assess Xray attributable RA magnetic resonance imaging ( MRI ) wrist metacarpophalangeal ( MCP ) joint dominant hand Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow baseline Rheumatic autoimmune disease rheumatoid arthritis Functional Class IV define American College Rheumatology ( ACR ) Classification Functional Status Rheumatoid Arthritis Diagnosis juvenile idiopathic arthritis juvenile RA and/or RA age 16 Prior history current inflammatory joint disease RA Exposure tocilizumab time prior baseline Treatment investigational agent within 4 week ( five halflives investigational drug , whichever long ) screen Previous treatment celldepleting therapy Treatment intravenous ( IV ) gamma globulin , plasmapheresis within 6 month baseline Intraarticular ( IA ) parenteral corticosteroid within 4 week prior baseline Any previous treatment alkylating agent chlorambucil , total lymphoid irradiation Treatment 2 antitumor necrosis factor ( TNF ) agents biologic agent time prior screen Evidence serious uncontrolled concomitant disease ( e.g. , cardiovascular , nervous system , pulmonary ) History diverticulitis , diverticulosis require antibiotic treatment , chromic ulcerative low gastrointestinal ( GI ) disease Crohn 's disease , ulcerative colitis , symptomatic low genitourinary ( GU ) condition might predispose perforation Known active current history recurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>